CD274 and cancer: In particular, due to the higher expression of programmed cell death ligand-1 (PD-L1) on TNBC compared to the other cancer subtypes, the IMpassion130 Trial [10] combined nab-paclitaxel with the anti-PD-L1 atezolizumab, and demonstrated a remarkably prolonged progression-free survival (PFS) in patients with metastatic TNBC, leading to FDA approval for patients with unresectable advanced PD-L1-positive TNBC even though the following IMpassion131 trial (NCT03125092) caused the withdrawal of atezolizumab [11].